OBT & Seattle Genetics join forces for antibody conjugates in cancer
This article was originally published in Scrip
Executive Summary
Signing its third deal in as many weeks, Oxford BioTherapeutics (OBT) has agreed to collaborate with Seattle Genetics to discover jointly novel antibody-drug conjugates (ADC) as potential cancer treatments. OBT will generate panels of monoclonal antibodies against novel tumour-specific antigens identified using its proprietary Oxford Genome Anatomy Project (OGAP) proteomic database. Seattle Genetics will use its ADC platform to screen the resulting monoclonals for activity.